🚀 VC round data is live in beta, check it out!
Ryvu Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ryvu Therapeutics and similar public comparables like Hamlet BioPharma, Karolinska Development, Fate Therapeutics, Cardiol Therapeutics and more.
Ryvu Therapeutics Overview
About Ryvu Therapeutics
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
Founded
2007
HQ
Employees
294
Website
Financials (LTM)
EV
$156M
Ryvu Therapeutics Financials
Ryvu Therapeutics reported last 12-month revenue of $32M and negative EBITDA of ($16M).
In the same LTM period, Ryvu Therapeutics generated ($16M) in EBITDA losses and had net loss of ($20M).
Revenue (LTM)
Ryvu Therapeutics P&L
In the most recent fiscal year, Ryvu Therapeutics reported revenue of $23M and EBITDA of ($23M).
Ryvu Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $32M | XXX | $23M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $13M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 58% | XXX | XXX | XXX |
| EBITDA | ($16M) | XXX | ($23M) | XXX | XXX | XXX |
| EBITDA Margin | (51%) | XXX | (100%) | XXX | XXX | XXX |
| EBIT Margin | (72%) | XXX | (119%) | XXX | XXX | XXX |
| Net Profit | ($20M) | XXX | ($28M) | XXX | XXX | XXX |
| Net Margin | (62%) | XXX | (124%) | XXX | XXX | XXX |
| Net Debt | — | — | $4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ryvu Therapeutics Stock Performance
Ryvu Therapeutics has current market cap of $165M, and enterprise value of $156M.
Market Cap Evolution
Ryvu Therapeutics' stock price is $7.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $156M | $165M | 0.1% | XXX | XXX | XXX | $-1.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRyvu Therapeutics Valuation Multiples
Ryvu Therapeutics trades at 4.9x EV/Revenue multiple, and (9.5x) EV/EBITDA.
EV / Revenue (LTM)
Ryvu Therapeutics Financial Valuation Multiples
As of April 20, 2026, Ryvu Therapeutics has market cap of $165M and EV of $156M.
Equity research analysts estimate Ryvu Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ryvu Therapeutics has a P/E ratio of (8.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $165M | XXX | $165M | XXX | XXX | XXX |
| EV (current) | $156M | XXX | $156M | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | (9.5x) | XXX | (6.9x) | XXX | XXX | XXX |
| EV/EBIT | (6.8x) | XXX | (5.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 11.8x | XXX | XXX | XXX |
| P/E | (8.4x) | XXX | (5.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ryvu Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ryvu Therapeutics Margins & Growth Rates
Ryvu Therapeutics' revenue in the last 12 month grew by 43%.
Ryvu Therapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Ryvu Therapeutics' rule of 40 is 218% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ryvu Therapeutics' rule of X is 523% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ryvu Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 43% | XXX | 132% | XXX | XXX | XXX |
| EBITDA Margin | (51%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | (104%) | XXX | (133%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 218% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 523% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 177% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ryvu Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ryvu Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Hamlet BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Karolinska Development | XXX | XXX | XXX | XXX | XXX | XXX |
| Fate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cardiol Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Galectin Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ryvu Therapeutics M&A Activity
Ryvu Therapeutics acquired XXX companies to date.
Last acquisition by Ryvu Therapeutics was on XXXXXXXX, XXXXX. Ryvu Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ryvu Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRyvu Therapeutics Investment Activity
Ryvu Therapeutics invested in XXX companies to date.
Ryvu Therapeutics made its latest investment on XXXXXXXX, XXXXX. Ryvu Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ryvu Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ryvu Therapeutics
| When was Ryvu Therapeutics founded? | Ryvu Therapeutics was founded in 2007. |
| Where is Ryvu Therapeutics headquartered? | Ryvu Therapeutics is headquartered in Poland. |
| How many employees does Ryvu Therapeutics have? | As of today, Ryvu Therapeutics has over 294 employees. |
| Is Ryvu Therapeutics publicly listed? | Yes, Ryvu Therapeutics is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Ryvu Therapeutics? | Ryvu Therapeutics trades under RVU ticker. |
| When did Ryvu Therapeutics go public? | Ryvu Therapeutics went public in 2011. |
| Who are competitors of Ryvu Therapeutics? | Ryvu Therapeutics main competitors are Hamlet BioPharma, Karolinska Development, Fate Therapeutics, Cardiol Therapeutics. |
| What is the current market cap of Ryvu Therapeutics? | Ryvu Therapeutics' current market cap is $165M. |
| What is the current revenue of Ryvu Therapeutics? | Ryvu Therapeutics' last 12 months revenue is $32M. |
| What is the current revenue growth of Ryvu Therapeutics? | Ryvu Therapeutics revenue growth (NTM/LTM) is 43%. |
| What is the current EV/Revenue multiple of Ryvu Therapeutics? | Current revenue multiple of Ryvu Therapeutics is 4.9x. |
| Is Ryvu Therapeutics profitable? | No, Ryvu Therapeutics is not profitable. |
| What is the current EBITDA of Ryvu Therapeutics? | Ryvu Therapeutics has negative EBITDA and is not profitable. |
| What is Ryvu Therapeutics' EBITDA margin? | Ryvu Therapeutics' last 12 months EBITDA margin is (51%). |
| What is the current EV/EBITDA multiple of Ryvu Therapeutics? | Current EBITDA multiple of Ryvu Therapeutics is (9.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.